NasdaqGM:MNKDBiotechs
MannKind (MNKD) Wins Breakthrough T1D Grant, Is The Stock Still 11% Undervalued?
What the Breakthrough T1D grant means for MannKind
The new Breakthrough T1D grant for MannKind (MNKD) and its INHALE-1 study puts Afrezza’s pediatric program in focus, coming shortly after FDA approval for children aged 6 and older.
For you as an investor, the grant does two things at once. It validates Afrezza as a research priority within the type 1 diabetes community, and it helps support clinical work that MannKind would otherwise need to fund on its own.
The INHALE-1 trial is centered on...